References
- Fernández-Vega González A, Fernández-Vega González C, Fernández-VegaSanz B, Mt P, Merayo-Lloves J. Bilateral fungal infection inducing a serpiginous-like picture. Eur J Ophthalmol. May, 2021;31(3):NP50–NP56. doi:10.1177/1120672120908726. Epub 2020 Feb 27. PMID: 32106701.
- Danielescu C, Stanca HT, Iorga RE, Darabus DM, Potop V. The diagnosis and treatment of fungal endophthalmitis: an update. Diagnostics. 2022; 12(3):679. doi: 10.3390/diagnostics12030679. PMCID: PMC8947249.
- Invernizzi A, Symes R, Miserocchi E, Cozzi M, Cereda M, Fogliato G, et al. Spectral domain optical coherence tomography findings in endogenous Candida endophthalmitis and their clinical relevance. Retina Phila Pa. 2018;38(5):1011–1018. doi: 10.1097/IAE.0000000000001630. PMID: 28492430
- Das T, Agarwal M, Anand AR, Behera UC, Bhende M, Das AV, et al. Fungal endophthalmitis: analysis of 730 consecutive eyes from 7 tertiary eye care centers in India. Ophthalmol Retina. March, 2022;6(3):243–251. doi: 10.1016/j.oret.2021.09.006. PMID: 34547530
- Selva Pandiyan A, Siva Ganesa Karthikeyan R, Rameshkumar G, Sen S, Lalitha P. Identification of bacterial and fungal pathogens by rDNA gene barcoding in vitreous fluids of endophthalmitis patients. Semin Ophthalmol. 2020;35(7–8):358–364. doi:10.1080/08820538.2020.1864416. Epub 2021 Jan 3. PMID: 33390091.
- Van Gelder RN. Applications of the polymerase chain reaction to diagnosis of ophthalmic disease. Surv Ophthalmol. 2001;46(3):248–258. doi:10.1016/s0039-6257(01)00274-0. PMID: 11738432.
- Gundacker ND, Baddley JW. FunGal infections in the era of biologic therapies. Curr Clin Micro Rpt. 2015;2(2):76–83. doi:10.1007/s40588-015-0018-y.
- Davis MR, Thompson GR 3rd, Patterson TF. Fungal infections potentiated by biologics. Infect Dis Clin North Am. 2020;34(2):389–411. doi:10.1016/j.idc.2020.02.010. Epub 2020 Apr 23. PMID: 32334987.
- Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124–131. doi:10.1093/rheumatology/keq242. Epub 2010 Jul 31. PMID: 20675706; PMCID: PMC3105607.
- Vallabhaneni S, Chiller TM. FungAl infections and new biologic therapies. Curr Rheumatol Rep. 2016;18(5):29. doi:10.1007/s11926-016-0572-1. PMID: 27032792.